Morepen Laboratories Q1 FY27 Results: Revenue Hits Record High, EBITDA Jumps 207%, PAT Soars 394%

What Happened ?

Morepen Laboratories recorded its strongest-ever quarterly performance, benefiting from improved operating leverage, recovery in the API business, robust export growth, and the successful commercialization of its large CDMO contract. The company completed commercial CDMO dispatches worth ₹58 crore during the quarter, marking the transition of its “Morepen 2.0” strategy from development to execution. The performance also reflected continued momentum in its Medical Devices business and sustained regulatory compliance across global manufacturing operations. 

key details

Business & Operational Highlights:

• Revenue increased 34% YoY to ₹575.31 crore.
• EBITDA surged 207% YoY to ₹87.72 crore.
• EBITDA margin expanded sharply to 15.25% from 6.65%.
• PAT grew 394% YoY to ₹56.35 crore.
• Export revenue more than doubled, increasing 111% YoY.
• API business recorded 31% growth, while API exports increased 42%.
• Medical Devices business grew 19% YoY.
• Commercial dispatches worth ₹58 crore were completed under the company’s ₹825 crore CDMO mandate during the quarter.
• The company completed its fourth consecutive USFDA inspection with Nil Form 483 observations, strengthening its regulatory credentials. 

Strategic Significance:

• The ₹825 crore CDMO mandate entered full-scale commercialization, marking a significant strategic milestone.
• The commercialization validates Morepen’s “Morepen 2.0” transformation strategy focused on:
  • Innovation-led manufacturing.
  • Long-duration CDMO partnerships.
  • Recurring customer programs.
  • A scalable operating platform.
• The company is expanding manufacturing capacity in phases, targeting up to 1,200 KL by FY30.
• Future technology investments will focus on:
  • Specialty APIs.
  • Complex chemistry.
  • High-potency manufacturing.
  • Advanced intermediates.
  • Peptides and new modalities over the long term.
• The Medical Devices business continues to scale with an installed base of approximately 20 million blood glucose meters and annual strip capacity of 500 million strips, supporting recurring revenue generation. 

Note:

• Management stated that the API business recovery, accelerating exports, growing Medical Devices segment, and commercial CDMO execution position Morepen for its next phase of profitable growth through capacity expansion, customer diversification, and deeper global pharmaceutical partnerships. 

Risk Analysis

Summary:

• Morepen delivered record quarterly performance, but future growth will depend on successfully scaling CDMO operations, executing capacity expansion, and maintaining global regulatory compliance.

Key Risks:

• Timely execution of CDMO commercialization and customer deliveries.
• Capacity expansion projects must be completed as planned.
• API pricing and export demand remain subject to global market conditions.
• Maintaining regulatory compliance remains critical for international growth.

Worst Case:

• Any delays in CDMO execution, weaker API demand, or regulatory setbacks could slow revenue growth and affect margin expansion despite the company’s strong order pipeline.

Risk Level: Medium

Company Commentary

Management highlighted the following during the quarter:

• Sushil Suri, Chairman & Managing Director, said Q1 FY27 validates Morepen’s transformation strategy, with record revenue, significant profitability improvement, and meaningful operating leverage.
• Management highlighted that the ₹825 crore CDMO mandate has entered full-scale commercial execution, reinforcing the company’s transition from a transaction-led API business to an innovation-led manufacturing platform built around long-term global partnerships.
• The company reiterated its focus on API profitability recovery, export growth, Medical Devices expansion, capacity augmentation, customer diversification, and strengthening scientific and compliance capabilities.